Gupta K, Balachandran I, Foy J, et al. Highlights of cardiovascular disease prevention studies presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023;25(6):309–21. https://doi.org/10.1007/s11883-023-01103-4.

Article  CAS  PubMed  Google Scholar 

Gupta K, Hirsch JR, Kalsi J, Patel V, Gad MM, Virani SS. Highlights of cardiovascular disease prevention studies presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023;25(1):31–41. https://doi.org/10.1007/s11883-022-01079-7.

Article  CAS  PubMed  Google Scholar 

• Shapiro MD, Bhatt DL. “Cholesterol-years” for ASCVD risk prediction and treatment∗. J Am Coll Cardiol. 2020;76(13):1517–20. https://doi.org/10.1016/j.jacc.2020.08.004. Provides context to the studies discussed here.

Article  PubMed  Google Scholar 

Nayor M, Brown KJ, Vasan RS. The molecular basis of predicting atherosclerotic cardiovascular disease risk. Circ Res. 2021;128(2):287–303. https://doi.org/10.1161/CIRCRESAHA.120.315890.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Virani SS, Ballantyne CM. Low-density lipoprotein cholesterol. Circulation. 2018;138(21):2326–9. https://doi.org/10.1161/CIRCULATIONAHA.118.034922. Provides context to the studies discussed here.

Article  PubMed  PubMed Central  Google Scholar 

Kitkungvan D, Johnson NP, Kirkeeide R, et al. Design and rationale of the randomized trial of comprehensive lifestyle modification, optimal pharmacological treatment and utilizing PET imaging for quantifying and managing stable coronary artery disease (the CENTURY study). Am Heart J. 2021;237:135–46. https://doi.org/10.1016/j.ahj.2021.03.012.

Article  CAS  PubMed  Google Scholar 

• Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925–46. https://doi.org/10.1093/eurheartj/ehac361. Laid the groundwork and provides context to the studies discussed here.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Nicholls SJ, Nissen SE, Fleming C, Urva S, Suico J, Berg PH, Linnebjerg H, Ruotolo G, Turner PK, Michael LF. Muvalaplin, an oral small molecule inhibitor of lipoprotein(a) formation: a randomized clinical trial. JAMA. 2023;330(11):1042–53. https://doi.org/10.1001/jama.2023.16503. Original article for the study discussed that was simultaneously published.

Koren MJ, Moriarty PM, Baum SJ, et al. Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a). Nat Med. 2022;28(1):96–103. https://doi.org/10.1038/s41591-021-01634-w.

Article  CAS  PubMed  Google Scholar 

O’Donoghue ML, G López JA, Knusel B, et al. Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE). Am Heart J. 2022;251:61–9. https://doi.org/10.1016/j.ahj.2022.05.004. Laid the groundwork and provides context to the studies discussed here.

Article  CAS  PubMed  Google Scholar 

Kronenberg F, Mora S, Stroes ESG, et al. Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society. Atherosclerosis. 2023;374:107–20. https://doi.org/10.1016/j.atherosclerosis.2023.04.012.

Article  CAS  PubMed  Google Scholar 

Virani SS, Koschinsky ML, Maher L, et al. Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis. 2022;73:32–40. https://doi.org/10.1016/j.pcad.2022.01.002.

Article  PubMed  Google Scholar 

O’Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387(20):1855–64. https://doi.org/10.1056/NEJMoa2211023.

Article  PubMed  Google Scholar 

Lindholt JS, Søgaard R, Rasmussen LM, et al. Five-year outcomes of the danish cardiovascular screening (DANCAVAS) trial. N Engl J Med. 2022;387(15):1385–94. https://doi.org/10.1056/NEJMoa2208681.

Article  Google Scholar 

•• Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–19. https://doi.org/10.1056/NEJMoa1912387. Laid the groundwork and provides context to the studies discussed here.

Article  CAS  PubMed  Google Scholar 

•• Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109–19. https://doi.org/10.1016/S2213-8587(22)00353-9. Laid the groundwork and provides context to the studies discussed here.

Article  CAS  PubMed  Google Scholar 

Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047–57. https://doi.org/10.1093/eurheartj/ehac615.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64. https://doi.org/10.1056/NEJMoa2215024.

Article  PubMed  Google Scholar 

Andersen PK, Gill RD. Cox’s regression model for counting processes: a large sample study. Ann Stat. 1982;10(4):1100–20. https://doi.org/10.1214/aos/1176345976.

Article  Google Scholar 

SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54. https://doi.org/10.1093/eurheartj/ehab309.

Article  CAS  Google Scholar 

Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study. BMC Med. 2022;20(1):13. https://doi.org/10.1186/s12916-021-02208-w.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol. 2020;75(20):2553–66. https://doi.org/10.1016/j.jacc.2020.03.057.

Article  CAS  PubMed  Google Scholar 

Stein EA, Turner T, Kereiakes DJ, Butcher B, Mangu P, Zhou R. Abstract 17222: Safety, tolerability and LDL-C reduction with LIB003 a novel anti-PCSK9 recombinant fusion protein: Results of open-label extension phase 2B study. Circulation. 2019;140(Suppl_1):A17222–A17222. https://doi.org/10.1161/circ.140.suppl_1.17222.

Article  Google Scholar 

•• Raal F, Fourie N, Scott R, Blom D, De Vries Basson M, Kayikcioglu M, Caldwell K, Kallend D, Stein E; LIBerate-HeFH Investigators. Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial. Eur Heart J. 2023;44(40):4272–80. https://doi.org/10.1093/eurheartj/ehad596. Original article for the study discussed that was simultaneously published.